Instrument Inactif

Communiqués Kuros Biosciences AG Swiss Exchange

Actions

CH0011025217

Recherche biotechnologique et médicale

Cours en clôture Swiss Exchange
- ^CHF	-

13/08	Bourse Zurich: les indices en vert, investisseurs rassurés par l'inflation US	AW
13/08	Kuros Biosciences AG publie ses résultats pour le premier semestre clos le 30 juin 2026	CI

Communiqués

13/08	Kuros Biosciences delivers 45% H1 2026 year-over-year sales growth and increases overall profitability	GL
17/06	Kuros Biosciences to showcase MagnetOs™ commercial momentum and plan for scalable quality growth at Capital Markets Day in Zürich	GL
07/05	Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth	GL
07/05	Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth	AQ
15/04	Annual General Meeting of Kuros Biosciences approves all resolutions	GL
14/04	Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026	GL
10/03	Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025	GL
13/01	Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences	GL
02/12	Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion	GL
02/12	Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion	AQ
26/11	Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference	GL
16/10/25	Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025	GL
30/09/25	Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025	GL
30/09/25	Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025	AQ
18/09/25	Kuros statement on media inquiry concerning former Board member	GL
04/09/25	Kuros Biosciences announces changes in the Board of Directors	GL
14/08/25	Kuros Biosciences : Interim Report 2025	PU
14/08/25	Kuros Biosciences : H1 2025 Financial Results & Strategic Outlook	PU
14/08/25	Kuros Biosciences Reports First Half of 2025 Results	GL
05/08/25	Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance	GL
14/05/25	Kuros Biosciences : Capital Markets Day Webcast Presentation Deck	PU
13/05/25	Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich	GL
15/04/25	Annual General Meeting of Kuros Biosciences approves all resolutions	GL
15/04/25	Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025	GL
15/04/25	Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025	AQ